**Supplemental Table 4. Adverse events.**

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **Lidocaine (N=241)** | **Placebo (N=237)** |
|  | **Total, all-cause mortality** | 6 (2.49) | 7 (2.95) |
|  | **Total, serious adverse events** | 105 (43.57) | 103 (43.46) |
| **Organ System** | **Event Name** | **Lidocaine (N=241)** | **Placebo (N=237)** |
| Blood and lymphatic system disorders | Acute blood loss anemia | 4 (1.66) | 3 (1.27) |
| Bleeding | 6 (2.49) | 7 (2.95) |
| Chylothorax | 0 (0) | 1 (0.42) |
| Coagulopathy | 0 (0) | 2 (0.84) |
| Thrombocytopenia | 8 (3.32) | 8 (3.38) |
| Cardiac disorders | Atrial fibrillation | 41 (17.01) | 41 (17.30) |
| Atrial dysrhythmia, sinus bradycardia | 0 (0) | 4 (1.69) |
| Atrioventricular block | 1 (0.41) | 1 (0.42) |
| Bradycardia | 1 (0.41) | 2 (0.84) |
| Cardiac arrest | 1 (0.41) | 0 (0) |
| Cardiac tamponade | 1 (0.41) | 0 (0) |
| Cardiogenic shock | 0 (0) | 4 (1.69) |
| Complete heart block | 7 (2.90) | 6 (2.53) |
| Congestive heart failure | 2 (0.83) | 0 (0) |
| Heart attack | 0 (0) | 1 (0.42) |
| Heart failure | 1 (0.41) | 2 (0.84) |
| Hemorrhagic shock | 2 (0.83) | 0 (0) |
| Hypertension | 6 (2.49) | 2 (0.84) |
| Hypotension | 8 (3.32) | 7 (2.95) |
| Hypovolemic shock | 1 (0.41) | 0 (0) |
| Junctional rhythm | 5 (2.07) | 3 (1.27) |
| Left bundle branch block | 0 (0) | 1 (0.42) |
| Pulseless electrical activity arrest | 1 (0.41) | 0 (0) |
| Pericarditis | 0 (0) | 3 (1.27) |
| Shock | 0 (0) | 1 (0.42) |
| Sinus tachycardia | 3 (1.24) | 2 (0.84) |
| Syncope | 0 (0) | 1 (0.42) |
| Trifascicular block | 0 (0) | 1 (0.42) |
| Ventricular tachycardia | 2 (0.83) | 5 (2.11) |
| Ventricular ectopy | 1 (0.41) | 0 (0) |
| Gastrointestinal disorders | Gastrointestinal bleed | 2 (0.83) | 0 (0) |
| Ileus | 2 (0.83) | 6 (2.53) |
| Irritable bowel syndrome | 1 (0.41) | 0 (0) |
| Nausea/vomiting/constipation | 0 (0) | 4 (1.69) |
| General disorders | Fluid overload | 1 (0.41) | 1 (0.42) |
| Pain | 1 (0.41) | 1 (0.42) |
| Prolonged hospitalization | 1 (0.41) | 0 (0) |
| Re-admission after fall | 2 (0.83) | 0 (0) |
| Immune system disorders | Anaphylactic or anaphylactoid reaction | 1 (0.41) | 0 (0) |
| Fever of non-specified origin | 0 (0) | 1 (0.42) |
| Phlebitis | 1 (0.41) | 1 (0.42) |
| Transfusion reaction | 0 (0) | 1 (0.42) |
| Infections and infestations | Bacteremia/sepsis | 1 (0.41) | 0 (0) |
| Haemophilus influenzae | 1 (0.41) | 0 (0) |
| Infection | 2 (0.83) | 0 (0) |
| Leukocytosis | 8 (3.32) | 7 (2.95) |
| MRSA | 2 (0.83) | 0 (0) |
| Sternal wound infection | 1 (0.41) | 0 (0) |
| Thrush | 0 (0) | 1 (0.42) |
| Ventilator associated pneumonia | 1 (0.41) | 0 (0) |
| Injury, poisoning, and procedural complications | Diaphragmatic tear | 1 (0.41) | 0 (0) |
| Pulmonary contusion | 3 (1.24) | 0 (0) |
| Metabolism and nutrition disorders | Hyperkalemia | 1 (0.41) | 0 (0) |
| Hypokalemia | 1 (0.41) | 0 (0) |
| Hyponatremia | 1 (0.41) | 2 (0.84) |
| Lactic acidosis | 1 (0.41) | 0 (0) |
| Metabolic acidosis | 0 (0) | 1 (0.42) |
| Protein malnutrition | 0 (0) | 1 (0.42) |
| Nervous system disorders | Aphasia | 0 (0) | 1 (0.42) |
| Confusion/encephalopathy | 0 (0) | 1 (0.42) |
| Continuous coma | 1 (0.41) | 0 (0) |
| Dysphagia | 1 (0.41) | 1 (0.42) |
| Hypothermia | 0 (0) | 1 (0.42) |
| Left vocal cord palsy | 0 (0) | 1 (0.42) |
| Parkinson’s disease | 0 (0) | 1 (0.42) |
| Renal and urinary disorders | Acute urinary retention | 0 (0) | 1 (0.42) |
| Acute kidney injury | 2 (0.83) | 6 (2.53) |
| Hematuria | 1 (0.41) | 0 (0) |
| Renal failure | 1 (0.41) | 1 (0.42) |
| Renal insufficiency | 7 (2.90) | 5 (2.11) |
| Urinary tract infection | 3 (1.24) | 1 (0.42) |
| Respiratory, thoracic, and mediastinal disorders | Bronchitis | 0 (0) | 1 (0.42) |
| Hemoptysis | 0 (0) | 1 (0.42) |
| Hemothorax | 2 (0.83) | 0 (0) |
| Hypoxemia | 3 (1.24) | 1 (0.42) |
| Pleural effusion | 5 (2.07) | 6 (2.53) |
| Pneumonia | 2 (0.83) | 2 (0.84) |
| Pneumothorax | 1 (0.41) | 1 (0.42) |
| Pulmonary congestion | 0 (0) | 1 (0.42) |
| Pulmonary edema | 2 (0.83) | 5 (2.11) |
| Respiratory distress | 1 (0.41) | 2 (0.84) |
| Respiratory failure | 4 (1.66) | 6 (2.53) |
| Subcutaneous air | 1 (0.41) | 0 (0) |
| Ventilation >48h | 1 (0.41) | 0 (0) |
| Surgical and medical procedures | Left brachial embolectomy | 1 (0.41) | 0 (0) |
| Left pleural effusion thoracentesis | 0 (0) | 1 (0.42) |
| Left ventricular assist device | 0 (0) | 1 (0.42) |
| Pacemaker placement | 6 (2.49) | 8 (2.38) |
| Re-exploration for bleeding | 4 (1.66) | 4 (1.69) |
| Reintubation | 0 (0) | 1 (0.42) |
| Suprapubic catheter placement | 0 (0) | 1 (0.42) |
| Thoracentesis | 0 (0) | 2 (0.84) |
| Vascular disorders | Deep vein thrombosis | 0 (0) | 2 (0.84) |
| Stroke | 2 (0.83) | 6 (2.53) |
|  | **Total, other (not including serious) adverse events** | 32 (14.11) | 34 (14.35) |
| **Organ System** | **Event Name** | **Lidocaine (N=241)** | **Placebo (N=237)** |
| Cardiac disorders | Atrial fibrillation | 34 (14.11) | 34 (14.35) |

Full enumeration of all serious adverse events and all non-serious adverse events that occurred at greater than 5% rate in study cohort. Table includes all 478 randomized subjects.